NEW YORK, June 25, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and development, today.
AXIM Biotechnologies Inc.
AXIM® Biotechnologies, Inc. (AXIM) is a world leader in research and development of cannabinoid-based pharmaceutical products.
Biotechnology
1d
5d
1m
6m
1y
Max
AXIM Biotechnologies Inc. News
25 Jun
AXIM® Biotechnologies Signs Supply Agreement to Register Cannabinoid Oral Care Products in Clinical Trials
05 Jun
FOX Business Features Opinion Article Authored by AXIM Biotechnologies, Inc. CEO on Why Legal CBD is Good f
AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has garnered news coverage for an...
03 Jun
AXIM® Biotechnologies, Inc. Signs Cannabinoid Product Supply Agreement with Healthcare Company for Clinical
AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has signed a cannabinoid product supply...
15 May
AXIM® Biotechnologies Announces Additional Purchase Order for Nutraceutical Product With Leading Direct Sel
NEW YORK, May 15, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech”, “AXIM”, or the “Company”), a world leader in cannabinoid research and development, today.
AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech”, “Axim”, or the “Company”), a world leader in cannabinoid research and development, today announced that the Company will be attending and presenting...
Dig beneath its rapid sales growth, and you'll find good reason why this pot stock is down 19% since the year began.
23 Apr
AXIM® Biotechnologies, Inc. Nutraceutical Division Receives Purchase Order for 50,000 Boxes of the Company’
NEW YORK, April 23, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today.
12 Apr
AXIM® Biotechnologies, Inc. Announces Attendance and Presentation by Chief Technology Officer Lekhram Chang
NEW YORK, April 12, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today.
09 Apr
AXIM® Biotech Enters Services Agreement With CRO to Begin Clinical Studies On Dronabinol and CBD Chewing Gu
AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with...
04 Apr
AXIM® Biotechnologies, Inc. Appoints Mauricio Javier Gatto-Bellora to Company’s Board of Directors
AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (AXIM), a world leader in cannabinoid research and development, today announced the appointment of Mauricio Javier Gatto-Bellora to...
About AXIM Biotechnologies Inc.
We were incorporated in the state of Nevada on November 18, 2010, as AXIM International, Inc. On July 24, 2014, we changed our name to AXIM Biotechnologies, Inc. to better reflect our current, expanded business operations. In early 2014, we discontinued our organic waste marketable by-product business to focus on our anticipated new business to become an innovative biotechnology company working on the treatment of pain, spasticity, anxiety, and other medical disorders with the application of known and novel cannabinoid-based products. Our focus is also on research, development and production of pharmaceutical, nutraceutical and cosmetic products.
AXIM is developing broad IP portfolio covering diverse aspects of both technology and clinical indications. Clinical development programs cover diverse indications including diseases with currently unmet or poorly met treatment needs and providing solutions with potentially significantly reduced side effects to the currently available ones.
Team
Lekhram Changoer
Chief Technology Officer
Prof. Renger Witkamp
Professor
John Zajicek
Professor
Dr. Arno Hazekamp
Advisor
Dr. Robert Ritch
Professor
Dr. Ilya Reznik
Dr. Jacques F. Meis
Dr. Donald Abrams
$ 0.02
0.25%
Open:
0.02
High:
0.02
Low:
0.02
Symbol:
AXIM
Contact info
Phone:
+1 844 294 6246
Address:
45 Rockefeller Plaza, New York, NY 10020, USA
